SCHEMBL269798

SCHEMBL269798

Cc1ccc(/C=N/NC(=O)c2scc(C)c2NC(=O)c2cccc(C(S)c3nc[nH]n3)c2)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 2/20 0.37
ALDH1A1 P00352 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 5/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
BLM P54132 1/20 0.35
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
RAB9A P51151 5/20 0.34
NPC1 O15118 4/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
NFKB1 P19838 2/20 0.34
NFKB2 Q00653 2/20 0.34
RELA Q04206 2/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269096 0.91 GUSB (0.40) CTDSP1ALDH1A1L3MBTL1POLBMAPT
SCHEMBL268098 0.89 CTDSP1 (0.37) CTDSP1ALDH1A1POLBMAPTHPGD
SCHEMBL270113 0.82 NPC1 (0.42) ALDH1A1L3MBTL1MAPTRAB9ANPC1
SCHEMBL266893 0.81 KMT2A (0.38) CTDSP1ALDH1A1POLBMAPTHPGD
SCHEMBL267434 0.81 MAPT (0.42) ALDH1A1POLBMAPTHPGDRAB9A
SCHEMBL268493 0.81 RAB9A (0.44) CTDSP1ALDH1A1L3MBTL1POLBMAPT
SCHEMBL274303 0.80 MAPT (0.39) CTDSP1ALDH1A1L3MBTL1POLBMAPT
SCHEMBL269451 0.80 GUSB (0.41) CTDSP1POLBMAPTHPGDRAB9A
SCHEMBL269799 0.80 MAPT (0.39) CTDSP1ALDH1A1L3MBTL1POLBMAPT
SCHEMBL268192 0.78 SLC34A2 (0.44) ALDH1A1POLBMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 CTDSP1 2003/4885ALDH1A1 3022/4885L3MBTL1 934/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 CTDSP1 1785/4885ALDH1A1 2872/4885L3MBTL1 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.